

## Common variants at 10 Genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways

Nicole Soranzo, Serena Sanna, Eleanor Wheeler, Christian Gieger, Dörte Radke, Josée Dupuis, Nabila Bouatia-Naji, Claudia Langenberg, Inga Prokopenko, Elliot Stolerman, Manjinder S. Sandhu, Matthew M. Heeney, Joseph M. Devaney, Muredach P. Reilly, Sally L. Ricketts, Christa Meisinger

### Angaben zur Veröffentlichung / Publication details:

Soranzo, Nicole, Serena Sanna, Eleanor Wheeler, Christian Gieger, Dörte Radke, Josée Dupuis, Nabila Bouatia-Naji, et al. 2010. "Common variants at 10 Genomic loci influence hemoglobin A1C levels via glycemic and nonglycemic pathways." *Diabetes* 59 (12): 3229–39. <https://doi.org/10.2337/db10-0502>.

# Common Variants at 10 Genomic Loci Influence Hemoglobin A<sub>1c</sub> Levels via Glycemic and Nonglycemic Pathways

Nicole Soranzo,<sup>1,2</sup> Serena Sanna,<sup>3</sup> Eleanor Wheeler,<sup>1</sup> Christian Gieger,<sup>4</sup> Dörte Radke,<sup>5</sup> Josée Dupuis,<sup>6,7</sup> Nabila Bouatia-Naji,<sup>8</sup> Claudia Langenberg,<sup>9</sup> Inga Prokopenko,<sup>10,11</sup> Elliot Stoleran,<sup>12,13,14</sup> Manjinder S. Sandhu,<sup>9,15,16</sup> Matthew M. Heeney,<sup>17</sup> Joseph M. Devaney,<sup>18</sup> Muredach P. Reilly,<sup>19,20</sup> Sally L. Ricketts,<sup>15</sup> et al.\*

**OBJECTIVE**—Glycated hemoglobin (HbA<sub>1c</sub>), used to monitor and diagnose diabetes, is influenced by average glycemia over a 2- to 3-month period. Genetic factors affecting expression, turnover, and abnormal glycation of hemoglobin could also be associated with increased levels of HbA<sub>1c</sub>. We aimed to identify such genetic factors and investigate the extent to which they influence diabetes classification based on HbA<sub>1c</sub> levels.

**RESEARCH DESIGN AND METHODS**—We studied associations with HbA<sub>1c</sub> in up to 46,368 nondiabetic adults of European descent from 23 genome-wide association studies (GWAS) and 8 cohorts with de novo genotyped single nucleotide polymorphisms (SNPs). We combined studies using inverse-variance meta-analysis and tested mediation by glycemia using conditional analyses. We estimated the global effect of HbA<sub>1c</sub> loci using a multilocus risk score, and used net reclassification to estimate genetic effects on diabetes screening.

**RESULTS**—Ten loci reached genome-wide significant association with HbA<sub>1c</sub>, including six new loci near *FN3K* (lead SNP/*P* value, rs1046896/*P* =  $1.6 \times 10^{-26}$ ), *HFE* (rs1800562/*P* =  $2.6 \times 10^{-20}$ ), *TM6RSS6* (rs855791/*P* =  $2.7 \times 10^{-14}$ ), *ANK1* (rs4737009/*P* =  $6.1 \times 10^{-12}$ ), *SPTA1* (rs2779116/*P* =  $2.8 \times 10^{-9}$ ) and *ATP11A/TUBGCP3* (rs7998202/*P* =  $5.2 \times 10^{-9}$ ), and four known HbA<sub>1c</sub> loci: *HK1* (rs16926246/*P* =  $3.1 \times 10^{-54}$ ), *MTNR1B* (rs1387153/*P* =  $4.0 \times 10^{-11}$ ), *GCK* (rs1799884/*P* =  $1.5 \times 10^{-20}$ ) and *G6PC2/ABCB11* (rs552976/*P* =  $8.2 \times 10^{-18}$ ). We show that associations with HbA<sub>1c</sub> are partly a function of hyperglycemia associated with 3 of the 10 loci (*GCK*, *G6PC2* and *MTNR1B*). The seven nonglycemic loci accounted for a 0.19 (% HbA<sub>1c</sub>) difference between the extreme 10% tails of the risk score, and would reclassify ~2% of a general white population screened for diabetes with HbA<sub>1c</sub>.

**CONCLUSIONS**—GWAS identified 10 genetic loci reproducibly associated with HbA<sub>1c</sub>. Six are novel and seven map to loci where rarer variants cause hereditary anemias and iron storage disorders. Common variants at these loci likely influence HbA<sub>1c</sub> levels

via erythrocyte biology, and confer a small but detectable reclassification of diabetes diagnosis by HbA<sub>1c</sub>. *Diabetes* 59: 3229–3239, 2010

Glycated hemoglobin (HbA<sub>1c</sub>) results from glycation, the nonenzymatic and mostly irreversible chemical modification by glucose of hemoglobin molecules carried in erythrocytes. The rate of glycation directly depends on ambient blood glucose levels, so HbA<sub>1c</sub> reflects the average concentration of blood glucose over the average life span of a erythrocyte (in humans, ~3 months), and represents a longer-term indicator of glycemic status compared to fasting glucose (FG) (1). In addition to ambient glycemia, it is known that medical conditions that change erythrocyte turnover (such as hemolytic anemias, chronic malaria, major blood loss, or blood transfusion), as well as genetic hereditary anemias and iron storage disorders (caused by rare variants in genes involved in erythrocyte membrane stability, hemoglobin function, erythrocyte glucose sensing, and membrane transport) may influence the variability of HbA<sub>1c</sub> in populations (2–4).

Common genetic variation also influences HbA<sub>1c</sub> variability. The heritability of HbA<sub>1c</sub> levels is relatively high (47–59%) when compared with FG (34–36%) or glucose levels as determined by 2-h postoral glucose tolerance test (33%) (5,6). Recent genome-wide association studies (GWAS) of FG have shown that single nucleotide polymorphisms (SNPs) near three loci (*G6PC2*, *MTNR1B*, and *GCK*) are also associated with HbA<sub>1c</sub> levels (7–15). A GWAS for HbA<sub>1c</sub> levels in 14,618 nondiabetic women found a suggestive association (*P* =  $9.8 \times 10^{-8}$ ) with *SLC30A8* (a known type 2 diabetes locus) and genome-wide significant association (*P* <  $5 \times 10^{-8}$ ) at a novel locus, *HK1*, where rare variants are known to be associated with nonspherocytic hemolytic anemia (16). This suggests that both glycemic and erythrocyte genetic factors are associated with variation in HbA<sub>1c</sub>, but a more thorough accounting of common variants comprising the genetic architecture of HbA<sub>1c</sub> is needed.

In this study we tested the hypothesis that additional common genetic factors are associated with HbA<sub>1c</sub>. We conducted a meta-analysis of GWAS in up to 46,368 nondiabetic individuals of European ancestry as part of the Meta-Analyses of Glucose and Insulin-Related Traits Consortium (MAGIC) effort. In addition to seeking new common variants affecting HbA<sub>1c</sub> levels, we sought to place the size of the effect of novel genetic findings into the

\*The entire author list is available in the APPENDIX, and the authors' institutional affiliations are available in the online appendix at <http://diabetes.diabetesjournals.org/cgi/content/full/db10-0502/DC1>.

Corresponding authors: Jose C. Florez, [jcflorez@partners.org](mailto:jcflorez@partners.org); Manuela Uda, [manuela.uda@inn.cnr.it](mailto:manuela.uda@inn.cnr.it); Nicholas J. Wareham, [nick.wareham@nrc-epid.cam.ac.uk](mailto:nick.wareham@nrc-epid.cam.ac.uk); Inês Barroso, [ib1@sanger.ac.uk](mailto:ib1@sanger.ac.uk); and James B. Meigs, [jmeigs@partners.org](mailto:jmeigs@partners.org).

Received 11 April 2010 and accepted 5 September 2010. Published ahead of print at <http://diabetes.diabetesjournals.org> on 21 September 2010. DOI: 10.2337/db10-0502.

N.S., S.S., E.W., C.G., and D.R. contributed equally to this study.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

TABLE 1  
Characteristics of 46,368 participants from 31 cohorts employed in the meta-analysis

Cohort	N males/ females	Age (years) men/women	BMI (kg/m <sup>2</sup> ) men/women	HbA <sub>1c</sub> (% NGSP) men/women	Fasting plasma glucose (mmol/l) men/women
ARIC	3,106/3,671	57.4 (5.7)/56.7 (5.6)	27.33 (3.89)/26.63 (5.30)	5.41 (0.38)/5.37 (0.36)	5.75 (0.50)/5.52 (0.50)
B58C-T1DGC	1,217/1,284	45.3 (0.3)/45.2 (0.3)	27.93 (4.12)/26.86 (5.5)	5.18 (0.48)/5.22 (0.51)	—
B58C-WTCCC	711/717	44.9 (0.4)/44.9 (0.4)	27.79 (4.21)/26.84 (5.41)	5.21 (0.68)/5.21 (0.51)	—
BLSA	253/235	72.2 (13.5)/67.2 (15.6)	26.99 (3.92)/25.87 (4.94)	5.44 (0.53)/5.45 (0.45)	5.25 (0.56)/4.99 (0.48)
Croatia	275/384	54.8 (15.0)/55.2 (15.8)	27.43 (3.65)/26.94 (4.59)	5.25 (0.49)/5.31 (0.55)	5.40 (0.66)/5.26 (0.65)
deCODE	170/172	66.1 (14.4)/63.8 (16.0)	28.20 (4.00)/28.0 (4.90)	5.80 (0.95)/5.77 (1.25)	—
DESIR	178/538	53.1 (5.6)/49.5 (8.5)	23.15 (1.16)/21.36 (1.85)	5.25 (0.38)/5.16 (0.38)	5.11 (0.32)/5.01 (0.38)
DGI	218/262	59.1 (10.6)/59.5 (10.6)	26.42 (3.12)/26.29 (4.29)	5.73 (0.56)/5.61 (0.59)	5.50 (0.52)/5.39 (0.45)
DIAGEN	429/571	59.0 (14.2)/59.0 (15.4)	27.08 (3.61)/26.80 (4.82)	5.59 (0.65)/5.50 (0.61)	—
Epic 5,000	1,732/1,627	57.6 (9.4)/54.0 (9.0)	25.75 (2.60)/24.84 (3.38)	5.19 (0.55)/5.08 (0.55)	—
EPIC cases	409/548	60.8 (8.9)/60.2 (9.1)	32.55 (2.53)/33.44 (3.24)	5.58 (0.97)/5.47 (0.62)	—
EPIC cohort	859/1,052	61.3 (9.3)/60.0 (9.2)	26.79 (3.31)/26.33 (4.36)	5.38 (0.56)/5.32 (0.57)	—
Fenland	606/772	44.4 (7.4)/45.4 (7.2)	27.56 (3.91)/26.59 (5.35)	5.42 (0.37)/5.37 (0.37)	5.01 (0.47)/4.74 (0.48)
FHS	886/1,110	54.7 (10.0)/54.1 (9.9)	27.85 (3.92)/26.13 (4.97)	5.24 (0.62)/5.25 (0.61)	5.36 (0.48)/5.14 (0.49)
GenomeEUtwin	0/568	—/55.1 (21.8)	—/24.6 (4.18)	—/5.11 (0.68)	—/5.24 (0.55)
HEALTH2000	580/625	49.1 (10.4)/51.7 (11.4)	25.69 (3.26)/25.32 (4.19)	5.22 (0.29)/5.06 (0.32)	5.34 (0.48)/5.17 (0.42)
Lolipop	582/188	53.2 (10.4)/51.2 (10.5)	27.49 (3.92)/26.74 (5.33)	5.05 (0.54)/5.34 (0.38)	5.51 (1.45)/5.35 (1.75)
LURIC	215/195	54.1 (12.6)/61.1 (11.1)	26.90 (3.60)/26.60 (4.00)	5.80 (0.60)/5.90 (0.60)	—
KORA F3	711/751	62.3 (10.2)/61.6 (10.1)	27.89 (3.49)/27.70 (4.95)	5.30 (0.38)/5.33 (0.31)	—
KORA S4	844/892	53.9 (8.9)/53.4 (8.8)	27.91 (3.87)/27.25 (4.89)	5.57 (0.46)/5.59 (0.45)	—
METSIM	1,789/0	57.0 (7.3)/—	26.63 (3.76)/—	5.56 (0.32)/—	—
NHANES III	468/746	51.3 (20.6)/51.4 (20.3)	26.92 (4.85)/26.37 (5.81)	5.38 (0.50)/5.15 (0.55)	—
NTR	513/939	47.7 (14.4)/43.3 (13.7)	25.58 (3.28)/24.59 (4.02)	5.27 (0.46)/5.28 (0.45)	5.53 (0.51)/5.32 (0.51)
ORCADES	298/353	53.7 (15.3)/52.2 (15.4)	27.79 (4.14)/27.30 (5.11)	5.40 (0.49)/5.41 (0.51)	5.45 (0.51)/5.18 (0.49)
Partners/Roche	291/357	52.7 (12.9)/52.5 (12.7)	27.80 (5.20)/27.10 (7.30)	5.49 (0.48)/5.47 (0.45)	—
PROCARDIS	687/144	60.5 (6.7)/62.8 (6.3)	27.65 (3.58)/28.11 (4.98)	5.98 (1.07)/6.17 (1.10)	—
SardiNIA	1,418/1,928	46.5 (17.1)/45.2 (16.0)	26.36 (3.99)/24.65 (4.82)	5.47 (0.52)/5.39 (0.45)	4.96 (0.59)/4.67 (0.54)
SHIP	1,696/1,842	49.0 (16.0)/47.0 (16.0)	27.30 (3.90)/26.60 (5.20)	5.3 (0.60)/5.2 (0.60)	—
Sorbs	254/376	46.6 (16.2)/46.4 (15.8)	26.90 (3.60)/26.7 (5.50)	5.35 (0.37)/5.36 (0.38)	5.47 (0.49)/5.21 (0.57)
SardiNIA stage2	555/890	46.4 (15.1)/46.3 (15.8)	26.36 (3.48)/24.61 (4.60)	5.45 (0.85)/5.31 (0.86)	—
Segovia	274/309	53 (12)/55 (12)	27.35 (3.15)/27.41 (4.68)	5.17(0.49)/5.17 (0.45)	—

Data are mean (SD). Fifteen cohorts were included in the fasting-glucose adjusted analysis shown in Table 2 (ARIC, BLSA, CROATIA, Fenland, FHS, DESIR, GENOMEUTWIN, Lolipop, NTR, ORCADES, SardiNIA, KORA F4, DGI, Sorbs and Health2000). BLSA, DGI, Fenland, FHS, KORA F4 and Sorbs were used for analyses that included 2-h glucose. The mean (mmol/l), SE and N for 2-h glucose levels for males and females, respectively, were: 6.96 (2.47) (236)/6.42 (2.04) (207) in BLSA; 5.75 (1.20) (209)/6.15 (1.25) (254) in DGI; 5.27 (1.41) (600)/5.16 (1.35) (757) in Fenland; 5.744 (1.614) (858)/5.992 (1.707) (1,067) in FHS; and 5.19 (2.02) (254)/5.54 (1.96) (376) in Sorbs. Fasting glucose was not available in KORA S4, thus conditional models were run in KORA F4, a follow-up visit of KORA S4 samples. Mean and SE 2-h glucose levels in males and females, respectively, were: 5.66 (0.67)/5.60 (0.57) for HbA<sub>1c</sub> and 5.82 (1.20)/5.40 (1.01) for glucose. Cohorts in italics provided only de novo genotyping data. The means for Hb (g/l, males/females) were 148.39 (10.29)/135.94 (9.55) (KORA F3), 148.21 (10.00)/134.51 (9.15) (KORA F4), 152.38 (11.33)/136.56 (10.38) (NHANES III) and 148.54 (12.12)/130.83 (11.60) (SardiNIA). The means for MCV (pg, males/females) were 92.32 (3.91)/90.74 (4.08) (KORA F3), 92.04 (4.23)/90.83 (4.38) (KORA F4), 89.69 (4.45)/89.40 (4.34) (NHANES III) and 87.29 (9.28)/85.64 (9.22) (SardiNIA). The means for MCH (fl, males/females) were 31.22 (1.51)/30.60 (1.64) (KORA F3), 31.50 (1.62)/30.89 (1.73) (KORA F4), 30.50 (1.74)/30.22 (1.67) (NHANES III) and 29.14 (3.60)/28.40 (3.69) (SardiNIA). The means for Iron (μmol/l, males/females) were 17.66 (5.34)/16.29 (5.25) (KORA F3), 22.41 (6.87)/20.53 (6.53) (KORA F4), 18.78 (6.53)/17.03 (6.96) (NHANES III) and 18.01 (6.23)/15.30 (5.98) (SardiNIA). The means for Transferrin (g/l, males/females) were 2.45 (0.33)/2.56 (0.36) (KORA F3), 2.51 (0.35)/2.54 (0.38) (KORA F4), n.a. (NHANES III) and 1.96 (0.52)/2.07 (0.579) (SardiNIA).

population perspective of diabetes screening and diagnosis. HbA<sub>1c</sub> levels have recently been recommended for this use based on high overlap between HbA<sub>1c</sub> distributions in populations without diabetes and those with subclinical (undiagnosed) diabetes, ease of measurement, and an established role as a treatment target in clinical diabetes (17,18). We estimated the degree to which these HbA<sub>1c</sub>-associated loci shifted the population level distribution of HbA<sub>1c</sub> and thereby influenced diabetes screening using HbA<sub>1c</sub>.

## RESEARCH DESIGN AND METHODS

**Cohort description, study design, and genotyping.** The cohorts included in this study were part of MAGIC (19). The characteristics of the population samples used in this analysis are shown in Table 1. All participants were adults of European ancestry from Europe or the U.S., and free of diabetes as

assessed by either clinical diagnosis, self-reported diabetes, diabetes treatment, or undiagnosed diabetes defined by FG  $\geq 7.0$  mmol/l. HbA<sub>1c</sub> (in percentages) was measured in all studies from fasting or nonfasting whole blood using NGSP-certified methods. We found remarkably consistent means and SD across studies, increasing confidence that laboratory variability had a minimal effect on the study results. A local research ethics committees approved all studies and all participants gave informed consent.

We carried out a meta-analysis including 35,920 participants from 23 cohorts with available HbA<sub>1c</sub> measurements and genotype data including  $\sim 2.5$ M genotyped and imputed autosomal SNPs. This sample size ensures 80% power to detect SNPs, explaining 0.12% of the trait variance at  $\alpha = 5 \times 10^{-8}$ . For 5 SNPs (rs1046896, rs16926246, rs1799884, rs1800562, and rs552976) that had been previously selected from an interim analysis of the first 10 participating cohorts ( $n = 14,898$ ), we obtained further data by genotyping up to 10,448 participants from 8 additional cohorts. The sample size for each SNP is thus related to the number of cohorts that were genotyped (up to 31) and to the specific call rate. Details on genotyping methodology, quality control metrics, and statistical analyses for each



cohort are shown in supplementary Table S1 in the online appendix available at <http://diabetes.diabetesjournals.org/cgi/content/full/db10-0502/DC1>. Additional details on imputation and quality control applied by each study are given in the online supplementary METHODS.

**Primary genome-wide association studies and meta-analysis.** In each cohort a linear regression model was fit using untransformed (percentage) HbA<sub>1c</sub> as the dependent variable to evaluate the additive effect of genotyped and imputed SNPs. HbA<sub>1c</sub> showed a mild deviation from normality in the majority of cohorts. Log-transformation did not significantly improve normality; nevertheless, such mild deviation did not result in an inflation of the test statistics suggestive of an excess of false positives, as indicated by a genomic correction  $\lambda$  very close to the expected value of 1.0; thus, we report untransformed (percentage) HbA<sub>1c</sub> results. The model was adjusted for age, sex, and other cohort-specific variables as applicable. Further details are given in the supplementary METHODS and supplementary Table S1. Regression estimates for each SNP were combined across studies in a meta-analysis using a fixed effect inverse-variance approach (justified by nonsignificant heterogeneity of effect sizes at all validated loci), as implemented in the METAL software. The individual cohort analysis results were corrected prior to performing the meta-analysis for residual inflation of the test statistic using the genomic control method if the  $\lambda$  coefficient was  $>1.0$  (20). Cohort-specific results for each of the 10 loci are given in supplementary Table S2. Heterogeneity across study-specific effect sizes was assessed using the standard  $\chi^2$  test implemented in METAL, Cochran's Q statistic and the  $I^2$  statistics (21). **Association with related traits and diseases.** Secondary analyses were carried out on 10 SNPs (rs2779116, rs552976, rs1800562, rs1799884, rs4737009, rs16926246, rs1387153, rs7998202, rs1046896, and rs855791) reaching genome-wide significance and including only the stronger of the 2 significant *ANK1* SNPs (see supplementary METHODS for additional information). A first goal was to detect "pleiotropic" effects on potentially related traits for the 10 loci. To this end we tested them for association with correlated intermediate traits (BMI, and glycemic and hematologic parameters, supplementary Table S3).

Further, we carried out association analyses of HbA<sub>1c</sub> levels conditional on FG levels (Table 3) and hematologic parameters (supplementary Table S4) to formally test mediation by glycemia or erythrocyte traits. Mediation is used here to distinguish it from confounding. A confounder is a characteristic associated with both exposure and outcome but is not on the causal pathway linking the two together. By contrast, a mediator is also associated with both exposure and outcome, but is on the causal pathway that may explain the association between them. Our mediation analyses decompose the association between a SNP and HbA<sub>1c</sub> into two paths. The first path links the SNP directly to HbA<sub>1c</sub>, and the second path links the SNP to HbA<sub>1c</sub> through a mediator, e.g., FG or hematologic parameters. A marked attenuation of the size of effect on HbA<sub>1c</sub> of the SNP in the conditional "mediation" model implies that the SNP (e.g., rs552976) acts on the mediator (e.g., FG), which in turn acts on HbA<sub>1c</sub> levels. Further details on these analyses are provided in the on-line supplementary METHODS.

Finally, we tested associations of the 10 loci with risk of type 2 diabetes or coronary artery disease (CAD) using adequately powered case-controlled meta-analyses. Association statistics with type 2 diabetes were obtained from a previous analysis of the MAGIC datasets or from the DIAGRAM+ meta-analysis (22). CAD associations were tested in this study using cohorts described in supplementary Table S5. The CAD analytic sample size assembled for this study had 80% power to detect associations at an  $\alpha$  level of  $5 \times 10^{-8}$  for a genotype relative risk of 1.14, and a risk allele frequency of 0.2.

**Estimates of genetic effect size.** We used several methods to evaluate the size of the genetic effect of HbA<sub>1c</sub>-associated SNPs: 1) we used regression to estimate in percentages the total variance in HbA<sub>1c</sub> explained by the 10 loci; 2) we calculated an additive genotype score based on the number of risk alleles at 7 (nonglycemic) or 10 (all) loci and then calculated the difference in HbA<sub>1c</sub> (%) between individuals in the top 10% of the genotype score distribution and those in the bottom 10% (supplementary METHODS); and 3) we used net reclassification analysis to gauge the effect of individual genotype on HbA<sub>1c</sub> distributions at the population level.

**Net reclassification analysis.** Variation in the measured level of HbA<sub>1c</sub> associated with nonglycemic genetic effects may affect the classification of individuals as diabetic or nondiabetic when screening general population samples using HbA<sub>1c</sub>. We used this relationship as a way to understand the clinical influence of the HbA<sub>1c</sub> loci when applied at the population level. We estimated the change in classification that occurred when accounting for effects of the seven loci presumed not to affect HbA<sub>1c</sub> via primarily glycemic mechanisms (*SPTA1*, *HFE*, *ANK1*, *HK1*, *ATP11A/TUBGCP3*, *FN3K*, and *TMPPSS6*) using the method of Pencina et al. (23). For this analysis we combined the Framingham Heart Study (FHS), and Atherosclerosis Risk In Communities (ARIC) European ancestry cohorts ( $N = 10,110$ ). ARIC and FHS have several characteristics suitable for this analysis: 1) they are population-based samples, thus allowing a test of diabetes screening in a truly unselected

sample; 2) they are of large sample size, thus maximizing the number of diabetic subjects that can readily be folded back for reclassification analysis; 3) they have both fasting glucose and HbA<sub>1c</sub> measured. We excluded as in previous analyses all individuals on diabetes treatment (diagnosed diabetes), but retained individuals with  $FG \geq 7.0$  mmol/l not on treatment (who we classified as having undiagnosed diabetes,  $N = 593$ ) as well as all nondiabetic individuals ( $N = 9,517$ ). We then sought to differentiate these individuals on the basis of their HbA<sub>1c</sub> levels, using  $\geq 6.5\%$  as the cutoff indicating diabetes. We counted the cumulative frequency distribution of measured HbA<sub>1c</sub> levels by diabetes status, then re-estimated the frequency distribution after regression analysis adjusting for the seven SNPs at the nonglycemic loci, recalibrating the distribution to have the same mean HbA<sub>1c</sub> as in each original cohort. We counted the proportion of undiagnosed diabetic individuals with unadjusted HbA<sub>1c</sub>  $\geq 6.5\%$  who had an adjusted HbA<sub>1c</sub>  $<6.5\%$ , and the proportion of nondiabetic individuals with unadjusted HbA<sub>1c</sub>  $<6.5\%$  who had an adjusted HbA<sub>1c</sub>  $\geq 6.5\%$ . The difference between these proportions is called "net reclassification" and in this instance indicates the overall proportion of a population whose diagnostic status would change based on the influence of these seven common, nonglycemic genetic variants.

## RESULTS

**New common variants associated with HbA<sub>1c</sub>.** We carried out a meta-analysis of SNP associations with HbA<sub>1c</sub> levels in up to 46,368 participants of European ancestry from 31 cohorts. We identified 10 genomic regions associated with HbA<sub>1c</sub> levels (Table 2, Figs. 1 and 2). Six associated regions were new, including *FN3K* (rs1046896,  $P = 1.57 \times 10^{-26}$ ), *HFE* (rs1800562,  $P = 2.59 \times 10^{-20}$ ), *TMPPSS6* (rs855791,  $P = 2.74 \times 10^{-4}$ ), *ANK1* (rs4737009,  $P = 6.11 \times 10^{-12}$ ), *SPTA1* (rs2779116,  $P = 2.75 \times 10^{-9}$ ), and *ATP11A/TUBGCP3* (rs7998202,  $P = 5.24 \times 10^{-9}$ ). A second, independent SNP near *ANK1* was also associated with HbA<sub>1c</sub> (rs6474359,  $P = 1.18 \times 10^{-8}$ ;  $r^2$  with rs4737009 = 0.0001; see also supplementary METHODS). In addition, SNPs in or near *HK1* (rs16926246,  $P = 3.11 \times 10^{-54}$ ), *MTNR1B* (rs1387153,  $P = 3.96 \times 10^{-11}$ ), *GCK* (rs1799884,  $P = 1.45 \times 10^{-20}$ ), and *G6PC2/ABCB11* (rs552976,  $P = 8.16 \times 10^{-18}$ ) were associated with HbA<sub>1c</sub> levels. These loci had previously been associated with HbA<sub>1c</sub> (15,16), FG (9–12,14,15) and/or type 2 diabetes risk (9–12,15,16,19). Associations were generally similar across cohorts, showing no significant heterogeneity (Table 2). This lack of heterogeneity suggests that there is good consistency in trait measurement across different cohorts.

**Pleiotropy and mediation of SNP-HbA<sub>1c</sub> associations.** HbA<sub>1c</sub> levels are influenced by average ambient glycemia over the preceding 3 months, and possibly by erythrocyte turnover. We therefore investigated the novel HbA<sub>1c</sub> loci for associations with several diabetes-related and hematologic quantitative parameters in the MAGIC cohorts (19,24) (supplementary Table S4). As previously shown (19), 3 of 10 loci, *GCK*, *MTNR1B*, and *G6PC2*, were associated with FG and HOMA-B (an index of  $\beta$ -cell function, Table 3 and supplementary Table S3), and *GCK* was additionally associated with 2-h glucose. In all cases, the allele associated with increased HbA<sub>1c</sub> was also associated with increased FG and 2-h glucose. No HbA<sub>1c</sub>-associated SNP was significantly associated with measures of insulin (supplementary Table S3). We further used conditional models to investigate whether FG levels mediated associations of SNPs with HbA<sub>1c</sub>. In these analyses a marked attenuation of the effect size of the SNP in a model adjusted for FG compared with the original main effects model would be consistent with the hypothesis that glycemic pathways primarily account for, or mediate, the HbA<sub>1c</sub> association. For the three loci associated with FG (*GCK*, *MTNR1B*, and *G6PC2/ABCB11*), effect sizes were

TABLE 2  
Associations with HbA<sub>1c</sub> of 10 independent loci identified in the meta-analysis

SNP	Chr	Pos (B36)	Nearest locus	Effect/ other allele	CEU freq (effect)	HbA <sub>1c</sub> (%) association				Heterogeneity		
						Freq (effect)	N	β (SE)	P	χ <sup>2</sup> P value	Q P	I <sup>2</sup> (%)
rs2779116	1	156,852,039	<i>SPTA1</i>	T/C	0.32	0.27	34,663	0.024 (0.004)	$2.75 \times 10^{-9}$	0.673	0.606	0
rs552976	2	169,616,945	<i>G6PC2/ ABCB11</i>	G/A	0.66	0.64	40,420*	0.047 (0.003)	$8.16 \times 10^{-18}$	0.596	0.591	0
rs1800562	6	26,201,120	<i>HFE</i>	G/A	0.96	0.94	43,778*	0.063 (0.007)	$2.59 \times 10^{-20}$	0.661	0.300	11
rs1799884	7	44,002,308	<i>GCK</i>	T/C	0.20	0.18	45,591*	0.038 (0.004)	$1.45 \times 10^{-20}$	0.187	0.120	24
rs6474359	8	41,668,351	<i>ANK1</i>	T/C	0.97	0.97	29,997	0.058 (0.011)	$1.18 \times 10^{-8}$	0.328	0.267	15
rs4737009	8	41,749,562	<i>ANK1</i>	A/G	0.28	0.24	36,862	0.027 (0.004)	$6.11 \times 10^{-12}$	0.182	0.182	21
rs16926246	10	70,763,398	<i>HK1</i>	C/T	0.89	0.90	42,707*	0.089 (0.004)	$3.11 \times 10^{-54}$	0.329	0.162	21
rs1387153	11	92,313,476	<i>MTNR1B</i>	T/C	0.28	0.28	32,293	0.028 (0.004)	$3.96 \times 10^{-11}$	0.867	0.857	0
rs7998202	13	112,379,869	<i>ATP11A/ TUBGCP3</i>	G/A	0.15	0.14	34,724	0.031 (0.005)	$5.24 \times 10^{-9}$	0.415	0.383	6
rs1046896	17	78,278,822	<i>FN3K</i>	T/C	0.25	0.31	45,953*	0.035 (0.003)	$1.57 \times 10^{-26}$	0.450	0.440	2
rs855791	22	35,792,882	<i>TMPRSS6</i>	A/G	0.39	0.42	34,562	0.027 (0.004)	$2.74 \times 10^{-14}$	0.970	0.962	0

\*Indicates SNPs for which additional de novo genotyping was performed in eight cohorts. The β coefficient denotes the per-effect allele increase in HbA<sub>1c</sub> (%) at that locus.

substantially decreased in FG-conditioned models, whereas at the other seven loci, effect sizes remained essentially unchanged (Table 3), indicating that associations with HbA<sub>1c</sub> at these loci are unlikely to be mediated by glycemic factors.

We also investigated associations of HbA<sub>1c</sub> loci with several hematologic parameters in a subset of four populations with available data (KORA F3, KORA F4, SardinIA, and NHANES III, supplementary Table S3). Two HbA<sub>1c</sub> loci (encoding for functional alleles at *HFE* and *TMPRSS6*) showed genome-wide significant association with erythrocyte indexes, consistent with an influence of erythrocyte physiology on HbA<sub>1c</sub> variability. The HbA<sub>1c</sub>-raising alleles had diverse effects, including associations with lower hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and iron, and higher transferrin (*HFE* and *TMPRSS6*). In addition, three loci (*SPTA1*, *ANK1*, and *HK1*) showed suggestive associations ( $P < 5 \times 10^{-3}$ ) with erythrocyte indexes, with HbA<sub>1c</sub>-raising alleles associated with increased MCV (*SPTA1*, *ANK1*), or lower hemoglobin (*HK1*).

We used these same four cohorts where those parameters were available to carry out a meta-analysis on HbA<sub>1c</sub> levels, this time conditioning for the hematologic traits. We did not observe any difference at the three “glycemic” loci, although attenuation of β estimates was observed at *HFE*, *TMPRSS6*, and *HK1* (supplementary Table S4). However, the sample size used for this analysis was relatively underpowered, resulting in nonsignificant differences ( $P$  value  $> 0.1$ ) and we lacked power for other loci, indicating the need for future analysis in larger sample collections.


**Associations with disease: type 2 diabetes and CAD risk.** HbA<sub>1c</sub> has been shown to have strong epidemiologic associations with type 2 diabetes risk and with CAD risk in persons without diabetes. To ascertain if the novel loci affected type 2 diabetes risk, we tested associations in well-powered datasets. In a previous meta-analysis of 40,655 type 2 diabetes cases and 87,022 controls in MAGIC (19), *MTNR1B*, and *GCK* showed significant evidence of association (rs1387153 OR = 1.09, 95% CI 1.06–1.12,  $P = 8.0 \times 10^{-13}$ ; rs1799884 OR = 1.07, 95% CI 1.05–1.10,  $P = 5.0 \times 10^{-8}$ ), whereas *G6PC2/ABCB11* did not (rs552976 OR = 0.97, 95% CI

0.95–0.99,  $P = 0.012$ ). We tested the other novel loci reported here for associations with type 2 diabetes in a partly overlapping study of 8,130 cases and 38,987 controls from the DIAGRAM+ consortium (22) (supplementary Table S3). No other locus associated with HbA<sub>1c</sub> was associated with type 2 diabetes risk.

We also tested for associations with CAD using data from nine case/control studies of European descent (13,925 cases and 14,590 controls, supplementary Table S5). None of the SNPs associated with HbA<sub>1c</sub> were associated with CAD in the combined sample of 28,515 participants (supplementary Table S6).

**Effect size estimates for HbA<sub>1c</sub>-associated loci.** In a regression model, the 10 loci combined explained ~2.4% of the total variance in HbA<sub>1c</sub> levels, or about 5% of estimated HbA<sub>1c</sub> heritability. We calculated a genotype score using four of the largest population-based studies (ARIC, SardinIA, KORA F4, and FHS). Using the 10 HbA<sub>1c</sub> loci, we estimated cohort-specific differences between the top and bottom 10% of the genotype score distribution (mean [SE] % HbA<sub>1c</sub>) to be: 5.25% (0.01) and 5.50% (0.004), respectively ( $P = 3.61 \times 10^{-33}$ ) for ARIC; 5.37% (0.027) and 5.49% (0.027) ( $P = 1.36 \times 10^{-3}$ ) for SardinIA; 5.32% (0.024) and 5.58% (0.027) ( $P = 4.64 \times 10^{-12}$ ) for KORA F4; and 5.07% (0.046) and 5.38% (0.046) ( $P = 1.45 \times 10^{-6}$ ) for FHS. The corresponding weighted average difference between the top and bottom 10% of the HbA<sub>1c</sub> distributions was 0.21%. For a genotype score using only the seven nonglycemic loci (*FN3K*, *HFE*, *TMPRSS6*, *ANK1*, *SPTA1*, *ATP11A/TUBGCP3*, and *HK1*), the weighted average difference between the top and bottom 10% of the HbA<sub>1c</sub> distributions was 0.19%.

**Net reclassification in diabetes screening with HbA<sub>1c</sub>.** We used net reclassification analysis to estimate the population-level impact of the seven nonglycemic loci when HbA<sub>1c</sub>  $\geq 6.5$  (%) is used as the reference cutoff for diabetes diagnosis, as recently proposed (18). We calculated the net reclassification around this threshold attributable to effects of the seven nonglycemic HbA<sub>1c</sub> loci that might be expected when screening a general European ancestry population for undiagnosed diabetes using HbA<sub>1c</sub>. We studied the FHS and ARIC cohorts combined ( $N = 10,110$ ), and included individuals with undiagnosed diabetes for detection by screening. We compared the



**FIG. 1.** Manhattan plot and quantile-quantile (QQ) plot of association findings. The figure summarizes the genome-wide association scan results combined across all studies by inverse variance weighting. The blue dotted line marks the threshold for genome-wide significance ( $5 \times 10^{-8}$ ). SNPs in loci exceeding this threshold are highlighted in green. A QQ plot is shown in the inset panel, where the red line corresponds to all test statistics, and the blue line to results after excluding statistics at all associated loci (highlighted in green in the Manhattan plot). The gray area corresponds to the 90% confidence region from a null distribution of  $P$  values (generated from 100 simulations). (A high-quality color representation of this figure is available in the online issue.)

measured distribution of HbA<sub>1c</sub> to the distribution adjusted for the seven nonglycemic SNPs (Fig. 3). The net reclassification was  $-1.86\%$  ( $P = 0.002$ ), indicating that the population-level effect size of the 7 nonglycemic HbA<sub>1c</sub>-associated SNPs is equivalent to reclassification of about 2% of an European ancestry population sample according to HbA<sub>1c</sub>-determined diabetes status.

## DISCUSSION


HbA<sub>1c</sub> levels are influenced by ambient glycemia, and also by erythrocyte biology, as seen in hereditary anemias and iron storage disorders caused by rare, highly-penetrant genetic variants. We analyzed associations of HbA<sub>1c</sub> levels with common genetic variants associated in a meta-analysis of up to 46,000 nondiabetic individuals of European descent from 31 cohorts. We identified 10 loci associated with HbA<sub>1c</sub> at genome-wide levels of significance, with 1 locus, *ANK1*, showing 2 independent signals. Of these, six (in or near *FN3K*, *HFE*, *TMPRSS6*, *ATP11A/TUBGCP3*, *ANK1*, and *SPTA1*) represent new common genetic determinants of HbA<sub>1c</sub>, and four (*GCK*, *G6PC2/ABCB11*, *MTNR1B*, and *HK1*) are confirmatory (9–11; 13–16; and 25).

Fasting and postprandial glucose levels are key determinants of HbA<sub>1c</sub>. Of the 10 loci identified, those in *GCK*,

*G6PC2*, and *MTNR1B* were strongly associated with levels of FG in this and previous studies (8; 10; 12–16; 19). Two of them (*GCK* and *MTNR1B*) were also associated with type 2 diabetes (19). Analyses conditioned on FG further supported an effect on HbA<sub>1c</sub> via regulation of systemic glucose concentrations for *GCK*, *G6PC2*, and *MTNR1B* loci alone. No other HbA<sub>1c</sub> locus was associated with type 2 diabetes risk or quantitative type 2 diabetes risk factors, suggesting that associations with HbA<sub>1c</sub> levels were not likely to be mediated by ambient glycemia. Rare variants at some of these loci (*HK1*, encoding hexokinase 1; *ANK1*, ankyrin; *SPTA1*, spectrin) cause hereditary anemias, and common variants at some loci are associated with quantitative hematologic traits as well as HbA<sub>1c</sub> (25,26). This is consistent with the hypothesis that these common variants influence HbA<sub>1c</sub> levels via erythrocyte physiology. Specific mechanisms are suggested by existing knowledge on the function of leading candidate genes in each region (see the supplemental on-line appendix).

*HK1* is a good example to consider mechanism of action of common variants, as it has confirmed support as a true-positive HbA<sub>1c</sub>-associated locus (16,27) and rare variants in *HK1* are associated with nonspherocytic hemolytic anemia (MIM 142600) (28,29). *HK1* encodes the erythrocyte isoform of hexokinase, which determines the intra-





**FIG. 2.** Regional association plots at the HbA<sub>1c</sub> loci. Each panel spans  $\pm 250$  kb around the most significant associated SNP in the region, which is highlighted with a blue square (panel C spans  $\pm 300$  kb). At the top of each panel, comb diagrams indicate the location of SNPs in the Illumina HumanMap 550K and Affymetrix 500K chips, and of SNPs imputed. The SNPs are colored according to their linkage disequilibrium with the top variant based on the CEU HapMap population (<http://www.hapmap.org>). Gene transcripts are annotated in the lower box, with the most likely biologic candidate highlighted in blue;  $\pm$  indicates the direction of transcription. In panel C, a few gene names were omitted for clarity. Here, genes are, from left to right, *SCGN*, *HIST1H2AA*, *HIST1H2BA*, *SLC17A4*, *SLC17A1*, *SLC17A3*, *SLC17A2*, *TRIM38*, *HIST1H1A*, *HIST1H3A*, *HIST1H4A*, *HIST1H4B*, *HIST1H3B*, *HIST1H2AB*, *HIST1H2BB*, *HIST1H3C*, *HIST1H1C*, *HFE*, *HIST1H4C*, *HIST1H1T*, *HIST1H2BC*, *HIST1H2AC*, *HIST1H1E*, *HIST1H2BD*, *HIST1H2BD*, *HIST1H2BE*, *HIST1H4D*, *HIST1H3D*, *HIST1H2AD*, *HIST1H2BF*, *HIST1H4E*, *HIST1H2BG*, *HIST1H2AE*, *HIST1H3E*, *HIST1H1D*, *HIST1H4F*, *HIST1H4G*, *HIST1H3F*, *HIST1H2BH*, *HIST1H3G*, *HIST1H2BI*, and *HIST1H4H*. In panel D, the names of the first two genes, *UBE2D4* and *WBSR19*, were also omitted for clarity. (A high-quality color representation of this figure is available in the online issue.)

cellular commitment of glucose to the glycolytic pathway by catalyzing the conversion of intracellular glucose to glucose-6-phosphate. One plausible explanation for the observed association lies in the potential dissociation between ambient plasma glucose and intracellular cytoplasmic glucose that might be induced by functional variants at *HK1*; since the enzyme is preferentially active in erythrocytes, the intracellular utilization (metabolism) of glucose may not be reflective of systemic levels of glycemia. In support of this notion, the HbA<sub>1c</sub>-raising allele was not associated with any glycemic traits in another recent study of European cohorts, but had robust associations with lower hemoglobin and hematocrit (27). In the CHARGE consortium, common variants in *HK1* were associated with decreased hemoglobin (25). We postulate, therefore, that the hemoglobin-lowering variant may affect the overall percentage of HbA<sub>1c</sub> through an increased glucose/hemoglobin molar ratio, which in turn could in-

crease the rate of hemoglobin that is glycated at a given glucose level. Variation in rates of deglycation and of erythrocyte turnover also are likely to play an important role in measured HbA<sub>1c</sub> levels. These hypotheses require further testing. A possible role of erythrocyte membrane stability and altered erythrocyte life span (*ANK1*, *SPTA1*) and hemoglobin deglycation (*FN3K*) may be postulated based on the known function of the respective gene products (supplementary online appendix).


A role for iron homeostasis influencing HbA<sub>1c</sub> is suggested by the *HFE* and *TMPRSS6* loci, where associations were observed at known functional variants in two complementary and directionally consistent pathways (30). At *HFE* the A allele at rs1800562 (Cys262Tyr), which is responsible for hereditary hemochromatosis (MIM 235200), was associated with lower levels of HbA<sub>1c</sub>, rather than the higher levels one would predict from epidemiologic observations of the increased *HFE* mutation preva-

TABLE 3  
Associations with HbA<sub>1c</sub> of 10 independent loci conditioned on levels of fasting or 2-h glucose

SNP	Nearest locus	Effect/ Other	Fasting glucose				2-h glucose			
			HbA <sub>1c</sub> (%) adjusted for sex, age	HbA <sub>1c</sub> (%) adjusted for glucose, sex, age	Fasting glucose (mmol/l) adjusted for sex, age	HbA <sub>1c</sub> (%) adjusted for sex, age	HbA <sub>1c</sub> (%) adjusted for 2-h glucose, sex, age	2-h glucose (mmol/l) adjusted for sex, age		
rs2779116	<i>SP7A1</i>	T/C	β (SE) P 0.019 (0.004) $2.4 \times 10^{-6}$	0.017 (0.004) $1.7 \times 10^{-6}$	-0.001 (0.005) 0.900	0.026 (0.008) $9.6 \times 10^{-4}$	0.029 (0.008) $2.9 \times 10^{-4}$	0.029 (0.037) 0.432		
rs552976	<i>G6PC2/ABCB11</i>	G/A	β (SE) P 0.028 (0.004) $4.5 \times 10^{-15}$	0.013 (0.003) $2.0 \times 10^{-5}$	0.060 (0.005) $6.3 \times 10^{-36}$	0.029 (0.007) $6.1 \times 10^{-5}$	0.027 (0.007) $1.4 \times 10^{-4}$	-0.021 (0.034) 0.538		
rs1800562	<i>HFE</i>	G/A	β (SE) P 0.054 (0.007) $3.1 \times 10^{-13}$	0.048 (0.006) $2.5 \times 10^{-14}$	-0.008 (0.010) 0.419	0.095 (0.016) $1.1 \times 10^{-9}$	0.096 (0.016) $1.1 \times 10^{-9}$	0.086 (0.073) 0.239		
rs1799884	<i>GCK</i>	T/C	β (SE) P 0.030 (0.005) $5.6 \times 10^{-11}$	0.018 (0.004) $7.3 \times 10^{-6}$	0.053 (0.0063) $4.7 \times 10^{-17}$	0.037 (0.010) $1.3 \times 10^{-4}$	0.039 (0.010) $6.2 \times 10^{-5}$	0.111 (0.046) 0.0143		
rs4737009	<i>ANKK1</i>	A/G	β (SE) P 0.023 (0.004) $3.2 \times 10^{-8}$	0.017 (0.004) $2.7 \times 10^{-6}$	0.010 (0.006) 0.072	0.023 (0.008) $4.4 \times 10^{-3}$	0.025 (0.008) $2.3 \times 10^{-3}$	-0.049 (0.038) 0.197		
rs16926246	<i>HK1</i>	C/T	β (SE) P 0.073 (0.007) $4.8 \times 10^{-26}$	0.069 (0.006) $6.4 \times 10^{-30}$	-0.013 (0.009) 0.178	0.010 (0.017) $1.6 \times 10^{-9}$	0.097 (0.017) $1.3 \times 10^{-8}$	0.012 (0.092) 0.899		
rs1387153	<i>MTNRI1B</i>	T/C	β (SE) P 0.027 (0.004) $1.9 \times 10^{-11}$	0.013 (0.004) $2.2 \times 10^{-4}$	0.056 (0.006) $1.8 \times 10^{-23}$	0.035 (0.008) $3.1 \times 10^{-5}$	0.032 (0.009) $1.5 \times 10^{-4}$	0.036 (0.040) 0.362		
rs7998202	<i>ATP11A/TUBGCP3</i>	G/A	β (SE) P 0.027 (0.006) $3.4 \times 10^{-6}$	0.023 (0.005) $1.3 \times 10^{-5}$	0.013 (0.008) 0.108	0.041 (0.012) $4.0 \times 10^{-4}$	0.035 (0.012) $2.6 \times 10^{-3}$	-0.035 (0.054) 0.512		
rs1046896	<i>FN3K</i>	T/C	β (SE) P 0.030 (0.004) $2.0 \times 10^{-16}$	0.026 (0.003) $1.0 \times 10^{-15}$	0.005 (0.005) 0.343	0.045 (0.008) $3.0 \times 10^{-9}$	0.043 (0.008) $2.0 \times 10^{-8}$	-0.011 (0.036) 0.753		
rs855791	<i>TM6RSS6</i>	A/G	β (SE) P 0.020 (0.004) $6.7 \times 10^{-8}$	0.019 (0.003) $8.3 \times 10^{-9}$	-0.006 (0.005) 0.223	0.024 (0.008) $1.7 \times 10^{-3}$	0.022 (0.008) $6.1 \times 10^{-3}$	0.009 (0.036) 0.815		

β (SE) is the per-effect allele increase in HbA<sub>1c</sub> (%) as in Table 2. For analyses conditional on fasting glucose, data were available for up to 23,654 samples from 15 cohorts (ARIC, BLSA, CROATIA, Fenland, FHS, DESIR, GENOMEUTWIN, Lohpop, NTR, ORCADES, Sardinia, KORAF4, DGI, Sorbs and Health2000). For analyses conditional on 2-h glucose, data were available for only a smaller set of six cohorts totaling up to 6,394 samples (BLSA, Fenland, FHS, KORAF4, DGI and Sorbs). The SNP association with HbA<sub>1c</sub> after adjusting for fasting glucose is attenuated most at the *G6PC2/ABCB11*, *GCK* and *MTNRI1B* loci. Associations at *ANKK1* are given for rs4737009, with the *ANKK1* SNP showing the strongest association with HbA<sub>1c</sub>.





**FIG. 3.** Net reclassification when screening for undiagnosed diabetes, using HbA<sub>1c</sub> as a population-level measure of genetic effect size. The figure shows the distribution of HbA<sub>1c</sub> in the FHS and ARIC cohorts combined ( $N = 10,110$ ), stratified by individuals with undiagnosed type 2 diabetes (UnDx DM,  $N = 593$ , *black lines*) or without diabetes (Non DM,  $N = 9,517$ , *gray lines*), and by HbA<sub>1c</sub> without adjustment (*solid lines*) or after adjustment for seven nonglycemic SNPs (*dashed lines*). The *vertical dashed line* is the diabetes diagnostic threshold at HbA<sub>1c</sub>  $\geq 6.5(\%)$ . Net reclassification is the overall proportion of the population appropriately moved above or below this line by considering the genetic information. For instance, among individuals with undiagnosed diabetes, 39.5% had an unadjusted HbA<sub>1c</sub> level  $\geq 6.5(\%)$  and 37.4% had a seven SNP-adjusted HbA<sub>1c</sub> level  $\geq 6.5(\%)$ , and among those with undiagnosed diabetes, 2.02% of those with undiagnosed diabetes were misclassified by the influence of the seven SNPs. The net reclassification is calculated as the difference  $-2.02\% - (-0.17\%) = -1.86\%$ .

lence in patients with type 2 diabetes (31,32). This apparently paradoxical relationship may be due to a shift in glucose to hemoglobin molar ratio associated with higher overall hemoglobin (supplementary Table S3), leading to consequent decrease in the percentage of glycated hemoglobin. The reciprocal observation is seen for *TM-PRSS6*, where the A allele at SNP rs855791 (Val736Ala) was associated with lower hemoglobin levels and *higher* HbA<sub>1c</sub> levels, as one would predict in a state of iron deficiency and disproportionately lower total hemoglobin concentrations.

It is known that conditions characterized by altered erythrocyte physiology may influence the utility of HbA<sub>1c</sub> in diabetes diagnosis (2–4,18), although this has generally been attributed to specific pathologies, such as inherited hemoglobinopathies, rather than to physiologic variation in the general population. We show here for the first time that the common genetic variation resulting in subtler but more widespread alteration of iron levels or hemoglobin concentration can also affect HbA<sub>1c</sub> levels. The absolute size of the genetic effect of 7 to 10 common SNPs associated with HbA<sub>1c</sub> is about 0.2%, comparing the extremes of the HbA<sub>1c</sub>-raising allele distribution. This is smaller than the 0.5% HbA<sub>1c</sub> average intralaboratory variation for HbA<sub>1c</sub>-certified labs reported as of 2000 (33). We sought to frame these genetic effects in population-level terms by comparing HbA<sub>1c</sub> distributions without and with adjustment for the seven nonglycemic SNPs and calculat-

ing net reclassification around the 6.5% HbA<sub>1c</sub> diagnostic threshold. We found the overall effect of the nonglycemic loci identified in this study to be small but detectable, potentially affecting about 2% of white individuals likely reclassified by diabetes status. This estimate represents an upper boundary for the effect of these common variants, as most people (the majority in the center of the distribution) are expected to have a smaller individual genotype effect size.

Our findings are therefore directly relevant to recent initiatives to focus diabetes diagnosis and care more centrally on HbA<sub>1c</sub>. Although the 10 loci described here likely represent the strongest common association signals found in Europeans, they account for a relatively small proportion of total variance of HbA<sub>1c</sub> and have minimal effect on diagnosis or misclassification of diabetes. Therefore, our study achieves a significant result in quantifying, for the first time, the misclassification risk associated with the top tier of HbA<sub>1c</sub>-associated common genetic variation. Future research will be required to explore two main areas not addressed in this study. First, genetic association studies in diabetic individuals will be important to assess the contribution of HbA<sub>1c</sub>-associated variants to its application in diabetes control. These analyses require different study designs to ours, and are beyond the scope of current datasets. Second, it will be important to explore associations of HbA<sub>1c</sub> with low to intermediate frequency variants through imputa-

tion from the 1,000 Genomes Project, direct association using whole-genome sequencing data, and in-depth replication and locus fine-mapping through custom arrays.

Finally, it will be important to evaluate reclassification rates in different populations, because the allele frequencies of some SNPs shown to be associated with HbA<sub>1c</sub> are known to vary substantially among populations with different ethnic ancestries. For instance, the A allele frequency at rs1800562 (*HFE*) in populations of European ancestry is 5% (CEU), but the A allele is absent in populations of African or East Asian ancestry (YRI, CHB/JPT). The T allele frequency at rs855791 (*TMPRSS6*) is 39% in CEU samples, but only 11 and 5% in the YRI and CHB/JPT samples, respectively. It will therefore be important to assess how variation in frequency and effect size influence the impact of HbA<sub>1c</sub>-associated variants in diverse populations.

In summary, in a meta-analysis of GWAS in a large number of individuals of European ancestry, we identified 10 common genetic loci associated with HbA<sub>1c</sub> levels. Six of these loci are novel, and seven appear to influence HbA<sub>1c</sub> via nonglycemic erythrocyte and iron biologic pathways. The genetic effect size of this set of loci on variations in HbA<sub>1c</sub> levels is small, but carries a detectable reclassification risk that will need to be refined by the discovery of additional variants and testing in diverse ancestral populations.

**URLs.** METAL, <http://www.sph.umich.edu/csg/abecasis/Metal/index.html>; HapMap, <http://www.hapmap.org>; R-project, <http://www.r-project.org>; 1,000 Genomes Project, <http://www.1000genomes.org>.

## ACKNOWLEDGMENTS

Disclosures are listed in the online appendix.

Parts of this study were presented in abstract form at the 70th Scientific Sessions of the American Diabetes Association, Orlando, Florida, 25–29 June 2010.

Acknowledgments are listed in the online appendix.

## APPENDIX

Nicole Soranzo,<sup>1,2</sup> Serena Sanna,<sup>3</sup> Eleanor Wheeler,<sup>1</sup> Christian Gieger,<sup>4</sup> Dörte Radke,<sup>5</sup> Josée Dupuis,<sup>6,7</sup> Nabila Bouatia-Naji,<sup>8</sup> Claudia Langenberg,<sup>9</sup> Inga Prokopenko,<sup>10,11</sup> Elliot Stolerman,<sup>12,13,14</sup> Manjinder S. Sandhu,<sup>9,15,16</sup> Matthew M. Heeney,<sup>17</sup> Joseph M. Devaney,<sup>18</sup> Muredach P. Reilly,<sup>19,20</sup> Sally L. Ricketts,<sup>15</sup> Alexandre F.R. Stewart,<sup>21</sup> Benjamin F. Voight,<sup>12,13,22</sup> Christina Willenborg,<sup>23,24</sup> Benjamin Wright,<sup>25</sup> David Altshuler,<sup>12,13,14</sup> Dan Arking,<sup>26</sup> Beverley Balkau,<sup>27,28</sup> Daniel Barnes,<sup>9</sup> Eric Boerwinkle,<sup>29</sup> Bernhard Böhm,<sup>30</sup> Amélie Bonnefond,<sup>8</sup> Lori L. Bonnycastle,<sup>31</sup> Dorret I. Boomsma,<sup>32</sup> Stefan R. Bornstein,<sup>33</sup> Yvonne Böttcher,<sup>34</sup> Suzannah Bumpstead,<sup>1</sup> Mary Susan Burnett-Miller,<sup>18</sup> Harry Campbell,<sup>35</sup> Antonio Cao,<sup>3</sup> John Chambers,<sup>36</sup> Robert Clark,<sup>37</sup> Francis S. Collins,<sup>31</sup> Josef Coresh,<sup>38</sup> Eco J.C. de Geus,<sup>32</sup> Mariano Dei,<sup>3</sup> Panos Deloukas,<sup>1</sup> Angela Döring,<sup>4</sup> Josephine M. Egan,<sup>39</sup> Roberto Elosua,<sup>40</sup> Luigi Ferrucci,<sup>41</sup> Nita Forouhi,<sup>9</sup> Caroline S. Fox,<sup>7,42</sup> Christopher Franklin,<sup>35</sup> Maria Grazia Franzosi,<sup>43</sup> Sophie Gallina,<sup>8</sup> Anuj Goel,<sup>11,44</sup> Jürgen Graessler,<sup>33</sup> Harald Grallert,<sup>4</sup> Andreas Greinacher,<sup>45</sup> David Hadley,<sup>46</sup> Alistair Hall,<sup>47</sup> Anders Hamsten on behalf of Procardis Consortium,<sup>48</sup> Caroline Hayward,<sup>49</sup> Simon Heath,<sup>50</sup> Christian Herder,<sup>51</sup> Georg Homuth,<sup>52</sup> Jouke-Jan Hottenga,<sup>32</sup> Rachel Hunter-Merrill,<sup>6</sup> Thomas Illig,<sup>4</sup> Anne U. Jackson,<sup>53</sup> Antti Jula,<sup>54</sup> Marcus Kleber,<sup>55</sup> Christopher W. Knouff,<sup>56</sup> Augustine

Kong,<sup>57</sup> Jaspal Kooner,<sup>58</sup> Anna Köttgen,<sup>59</sup> Peter Kovacs,<sup>60</sup> Knut Krohn,<sup>60</sup> Brigitte Kühnel,<sup>4</sup> Johanna Kuusisto,<sup>61</sup> Markku Laakso,<sup>61</sup> Mark Lathrop,<sup>62</sup> Cécile Lecoeur,<sup>8</sup> Man Li,<sup>59</sup> Mingyao Li,<sup>63</sup> Ruth J.F. Loos,<sup>9</sup> Jian'an Luan,<sup>9</sup> Valeriya Lyssenko,<sup>64</sup> Reedik Mägi,<sup>10,11</sup> Patrik K.E. Magnusson,<sup>65</sup> Anders Mälarstig,<sup>48</sup> Massimo Mangino,<sup>2</sup> Maria Teresa Martínez-Larrad,<sup>66,67</sup> Winfried März,<sup>55</sup> Wendy L. McArdle,<sup>68</sup> Ruth McPherson,<sup>21</sup> Christa Meisinger,<sup>4</sup> Thomas Meitinger,<sup>69,70</sup> Olle Melander,<sup>64</sup> Karen L. Mohlke,<sup>71</sup> Vincent E. Mooser,<sup>56</sup> Mario A. Morken,<sup>31</sup> Narisu Narisu,<sup>31</sup> David M. Nathan,<sup>14,72</sup> Matthias Nauck,<sup>73</sup> Chris O'Donnell,<sup>7</sup> Konrad Oexle,<sup>69</sup> Nazario Olla,<sup>3</sup> James S. Pankow,<sup>74</sup> Felicity Payne,<sup>1</sup> John F. Peden,<sup>11,44</sup> Nancy L. Pedersen,<sup>65</sup> Leena Peltonen,<sup>1,75,76</sup> Markus Perola,<sup>76,77</sup> Ozren Polasek,<sup>78,79</sup> Eleonora Porcu,<sup>3</sup> Daniel J. Rader,<sup>19,20</sup> Wolfgang Rathmann,<sup>80</sup> Samuli Ripatti,<sup>76,77</sup> Ghislain Rocheleau,<sup>81,82</sup> Michael Roden,<sup>51,83</sup> Igor Rudan,<sup>35,84</sup> Veikko Salomaa,<sup>77</sup> Richa Saxena,<sup>12,13</sup> David Schlessinger,<sup>85</sup> Heribert Schunkert,<sup>24</sup> Peter Schwarz,<sup>33</sup> Udo Sedorf,<sup>86</sup> Elizabeth Selvin,<sup>38</sup> Manuel Serrano-Rios,<sup>66,67</sup> Peter Shrader,<sup>87</sup> Angela Silveira,<sup>48</sup> David Siscovick,<sup>88</sup> Kjioung Song,<sup>56</sup> Timothy D. Spector,<sup>2</sup> Kari Stefansson,<sup>89,90</sup> Valgerdur Steinthorsdottir,<sup>89</sup> David P. Strachan,<sup>46</sup> Rona Strawbridge,<sup>48</sup> Michael Stumvoll,<sup>34,91</sup> Ida Surakka,<sup>76,77</sup> Amy J. Swift,<sup>31</sup> Toshiko Tanaka,<sup>41,92</sup> Alexander Teumer,<sup>52</sup> Gudmar Thorleifsson,<sup>57</sup> Unnur Thorsteinsdottir,<sup>89,90</sup> Anke Tönjes,<sup>34</sup> Gianluca Usala,<sup>3</sup> Veronique Vitart,<sup>49</sup> Henry Völzke,<sup>5</sup> Henri Wallaschofski,<sup>73</sup> Dawn M. Waterworth,<sup>56</sup> Hugh Watkins,<sup>11,44</sup> H-Erich Wichmann,<sup>4,93,94</sup> Sarah H. Wild,<sup>35</sup> Gonneke Willemsen,<sup>32</sup> Gordon H. Williams,<sup>14,42</sup> James F. Wilson,<sup>35</sup> Juliane Winkelmann,<sup>69,70,95</sup> Alan F. Wright,<sup>49</sup> WTCCC,<sup>96</sup> Carina Zabena,<sup>66,67</sup> Jing Hua Zhao,<sup>9</sup> Stephen E. Epstein,<sup>18</sup> Jeanette Erdmann,<sup>24</sup> Hakon H. Hakonarson,<sup>97</sup> Sekar Kathiresan,<sup>12,13,14,98</sup> Kay-Tee Khaw,<sup>99</sup> Robert Roberts,<sup>21</sup> Nilesh J. Samani,<sup>47</sup> Mark D. Fleming,<sup>100</sup> Robert Sladek,<sup>81,82</sup> Gonçalo Abecasis,<sup>53</sup> Michael Boehnke,<sup>53</sup> Philippe Froguel,<sup>8,101</sup> Leif Groop,<sup>64</sup> Mark I. McCarthy,<sup>10,11,102</sup> W.H. Linda Kao,<sup>103</sup> Jose C. Florez,<sup>12,13,14,72</sup> Manuela Uda,<sup>3</sup> Nicholas J. Wareham,<sup>9</sup> Inês Barroso,<sup>1</sup> and James B. Meigs.<sup>14,87</sup>

## REFERENCES

1. Mortensen HB, Christophersen C. Glucosylation of human haemoglobin in red blood cells studied in vitro. Kinetics of the formation and dissociation of haemoglobin HbA<sub>1c</sub>. Clin Chim Acta 1983;134:317–326
2. Panzer S, Kronik G, Lechner K, Bettelheim P, Neumann E, Dudczak R. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982;59:1348–1350
3. Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciralo PJ, Palascak MB, Joiner CH. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbHbA<sub>1c</sub>. Blood 2008;112:4284–4291
4. Roberts WL, Safar-Pour S, De BK, Rohlfing CL, Weykamp CW, Little RR. Effects of hemoglobin C and S traits on glycohemoglobin measurements by eleven methods. Clin Chem 2005;51:776–778
5. Meigs JB, Panhuysen CI, Myers RH, Wilson PW, Cupples LA. A genome-wide scan for loci linked to plasma levels of glucose and HbA<sub>1c</sub> in a community-based sample of Caucasian pedigrees: the Framingham Offspring Study. Diabetes 2002;51:833–840
6. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, Lai S, Usala G, Lai M, Loi P, Mameli C, Vacca L, Deiana M, Olla N, Masala M, Cao A, Najjar SS, Terracciano A, Nedorezov T, Sharov A, Zonderman AB, Abecasis GR, Costa P, Lakatta E, Schlessinger D. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet 2006;2:e132
7. McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep 2009;9:164–171
8. Weedon MN, Clark VJ, Qian Y, Ben-Shlomo Y, Timpson N, Ebrahim S, Lawlor DA, Pembrey ME, Ring S, Wilkin TJ, Voss LD, Jeffery AN, Metcalf B, Ferrucci L, Corsi AM, Murray A, Melzer D, Knight B, Shields B, Smith GD, Hattersley AT, Di Rienzo A, Frayling TM. A common haplotype of the

- glucokinase gene alters fasting glucose and birth weight: association in six studies and population-genetics analyses. *Am J Hum Genet* 2006;79:991–1001
9. Sparso T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL, Albrechtsen A, Rasmussen SS, Jorgensen T, Borch-Johnsen K, Sandbaek A, Lauritzen T, Madsbad S, Hansen T, Pedersen O. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. *Diabetologia* 2008;51:70–75
  10. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, Loos RJ, Manning AK, Jackson AU, Aulchenko Y, Potter SC, Erdos MR, Sanna S, Hottenga JJ, Wheeler E, Kaakinen M, Lyssenko V, Chen WM, Ahmadi K, Beckmann JS, Bergman RN, Bochud M, Bonnycastle LL, Buchanan TA, Cao A, Cervino A, Coin L, Collins FS, Crisponi L, de Geus EJ, Dehghan A, Deloukas P, Doney AS, Elliott P, Freimer N, Gateva V, Herder C, Hofman A, Hughes TE, Hunt S, Illig T, Inouye M, Isomaa B, Johnson T, Kong A, Krestyaninova M, Kuusisto J, Laakso M, Lim N, Lindblad U, Lindgren CM, McCann OT, Mohlke KL, Morris AD, Naitza S, Orru M, Palmer CN, Pouta A, Randall J, Rathmann W, Saramies J, Scheet P, Scott LJ, Scuteri A, Sharp S, Sijbrands E, Smit JH, Song K, Steinthorsdottir V, Stringham HM, Tuomi T, Tuomilehto J, Uitterlinden AG, Voight BF, Waterworth D, Wichmann HE, Willemens G, Witteman JC, Yuan X, Zhao JH, Zeggini E, Schlessinger D, Sandhu M, Boomsma DI, Uda M, Spector TD, Penninx BW, Altshuler D, Vollenweider P, Jarvelin MR, Lakatta E, Waeber G, Fox CS, Peltonen L, Groop LC, Mooser V, Cupples LA, Thorsteinsdottir U, Boehnke M, Barroso I, Van Duijn C, Dupuis J, Watanabe RM, Stefansson K, McCarthy MI, Wareham J, Meigs JB, Abecasis GR. Variants in MTNR1B influence fasting glucose levels. *Nat Genet* 2009;41:77–81
  11. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos C, Tewhey R, Rieder MJ, Hall J, Abecasis G, Tai ES, Welch C, Arnett DK, Lyssenko V, Lindholm E, Saxena R, de Bakker PI, Burt N, Voight BF, Hirschhorn JN, Tucker KL, Hedner T, Tuomi T, Isomaa B, Eriksson KF, Taskinen MR, Wahlstrand B, Hughes TE, Parnell LD, Lai CQ, Berglund G, Peltonen L, Vartiainen E, Jousilahti P, Havulinna AS, Salomaa V, Nilsson P, Groop L, Altshuler D, Ordovas JM, Kathiresan S. Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. *Diabetes* 2008;57:3112–3121
  12. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spiegel P, Bugliani M, Saxena R, Fex M, Pulizzi N, Isomaa B, Tuomi T, Nilsson P, Kuusisto J, Tuomilehto J, Boehnke M, Altshuler D, Sundler F, Eriksson JG, Jackson AU, Laakso M, Marchetti P, Watanabe RM, Mulder H, Groop L. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. *Nat Genet* 2009;41:82–88
  13. Chen WM, Erdos MR, Jackson AU, Saxena R, Sanna S, Silver KD, Timpson NJ, Hansen T, Orru M, Grazia Piras M, Bonnycastle LL, Willer CJ, Lyssenko V, Shen H, Kuusisto J, Ebrahim S, Sestu N, Duren WL, Spada MC, Stringham HM, Scott LJ, Olla N, Swift AJ, Najjar S, Mitchell BD, Lawlor DA, Smith GD, Ben-Shlomo Y, Andersen G, Borch-Johnsen K, Jorgensen T, Saramies J, Valle TT, Buchanan TA, Shuldiner AR, Lakatta E, Bergman RN, Uda M, Tuomilehto J, Pedersen O, Cao A, Groop L, Mohlke KL, Laakso M, Schlessinger D, Collins FS, Altshuler D, Abecasis GR, Boehnke M, Scuteri A, Watanabe RM. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. *J Clin Invest* 2008;118:2620–2628
  14. Bouatia-Naji N, Rocheleau G, Van Lommel L, Lemaire K, Schuit F, Cavalcanti-Proenca C, Marchand M, Hartikainen AL, Sovio U, De Graeve F, Rung J, Vaxillaire M, Tichet J, Marre M, Balkau B, Weill J, Elliott P, Jarvelin MR, Meyre D, Polychronakos C, Dina C, Sladek R, Froguel P. A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. *Science* 2008;320:1085–1088
  15. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, De Graeve F, Chevre JC, Borch-Johnsen K, Hartikainen AL, Ruokonen A, Tichet J, Marre M, Weill J, Heude B, Tauber M, Lemaire K, Schuit F, Elliott P, Jorgensen T, Charpentier G, Hadjadj S, Cauchi S, Vaxillaire M, Sladek R, Visvikis-Siest S, Balkau B, Levy-Marchal C, Pattou F, Meyre D, Blakemore AI, Jarvelin MR, Walley AJ, Hansen T, Dina C, Pedersen O, Froguel P. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. *Nat Genet* 2009;41:89–94
  16. Pare G, Chasman DI, Parker AN, Nathan DM, Miletich JP, Zee RY, Ridker PM. Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. *PLoS Genet* 2008;4:e1000312
  17. Selvin E, Zhu H, Brancati FL. Elevated HbA<sub>1c</sub> in adults without a history of diabetes in the U.S. *Diabetes Care* 2009;32:828–833
  18. International Expert Committee report on the role of the HbA<sub>1c</sub> assay in the diagnosis of diabetes. *Diabetes Care* 2009;32:1327–1334
  19. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, Wheeler E, Glazer NL, Bouatia-Naji N, Gloy AL, Lindgren CM, Mägi R, Morris AP, Randall J, Johnson T, Elliott P, Rybin D, Thorleifsson G, Steinthorsdottir V, Henneman P, Grallert H, Dehghan A, Hottenga JJ, Franklin CS, Navarro P, Song K, Goel A, Perry JRB, Egan JM, Lajunen T, Grarup N, Sparso T, Doney A, Voight B, Stringham HM, Li M, Kanoni S, Shrader P, Cavalcanti-Proença C, Kumari M, Qi L, Timpson NJ, Gieger C, Zabena C, Rocheleau G, Ingelsson E, An P, O'Connell J, Luan J, Elliott A, McCarrall SA, Payne F, Rocaesecca RM, Pattou F, Sethupathy P, Ardlie K, Ariyurek Y, Balkau B, Barter P, Beilby JP, Ben-Shlomo Y, Benediktsson R, Bennett AJ, Bergmann S, Bochud M, Boerwinkle E, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Bumpstead SJ, Charpentier G, Chen Y, Chines P, Clarke R, Coin LJM, Cooper MN, Cornelis M, Crawford G, Crisponi L, Day INM, de G. E., Delplanque J, Dina C, Erdos MR, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Fox CS, Frants R, Franzosi MG, Galan P, Goodarzi MO, Graessler J, Groves C, Grundy S, Gwilliam R, Gyllenstein U, Hadjadj S, Hallmans G, Hammond N, Han X, Hartikainen A, Hassanali N, Hayward C, Heath SC, Herberg S, Herder C, Hicks AA, Hillman DR, Hingorani AD, Hofman A, Hui J, Hung J, Isomaa B, Johnson PRV, Jørgensen T, Julia A, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimäki M, Knight B, Koskinen S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor D, Bacquer OL, Lecoeur C, Li Y, Lyssenko V, Mahley R, Mangino M, Manning AK, Martínez-Larrad MT, McAteer JB, McCulloch LJ, McPherson R, Meisinger C, Melzer D, Meyre D, Mitchell BD, Morken MA, Mukherjee S, Naitza S, Narisu N, Neville MJ, Oostra BA, Orru M, Pakyz R, Palmer CNA, Paoalisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Perola M, Pfeiffer AFH, Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Psaty BM, Rathmann W, Rayner NW, Rice K, Ripatti S, Rivadeneira F, Roden M, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, Sayer AA, Scheet P, Scott L, Seedorf U, Sharp SJ, Shields B, Sigurdsson G, Sijbrands EJG, Silveira A, Simpson L, Singleton A, Smith N, Sovio U, Swift A, Syddall H, Syvänen A, Tanaka T, Thorand B, Tichet J, Tönjes A, Tuomi T, Uitterlinden AG, van D, K. W., van H, M., Varma D, Visvikis-Siest S, Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Walters GB, Ward KL, Watkins H, Weedon MN, Wild SH, Willemens G, Witteman JCM, Yarnell JWG, Zeggini E, Zelenika D, Zethelius B, Zhai G, Zhao JH, Zillikens MC, Consortium. D, Consortium. G, Consortium. GB, Borecki IB, Loos RJJ, Meneton P, Magnusson PKE, Nathan DM, Williams GH, Hattersley AT, Silander K, Salomaa V, Smith GD, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner AR, Cooper C, Dedoussis GV, Serrano-Rios M, Morris AD, Lind L, Palmer LJ, Hu F, Franks PW, Ebrahim S, Marmot M, Kao WHL, Pankow JS, Sampson MJ, Kuusisto J, Laakso M, Hansen T, Pedersen O, Pramstaller PP, Wichmann H-E, Illig T, Rudan I, Wright AF, Stumvoll M, Campbell H, Wilson JF, Hamsten A, on behalf of, Procardis, consortium., Bergman RN, Buchanan TA, Collins FS, Mohlke KL, Tuomilehto J, Valle TT, Altshuler D, Rotter JJ, Siscovick DS, Penninx BWJH, Boomsma DI, Deloukas P, Spector TD, Frayling TM, Ferrucci L, Kong A, Thorsteinsdottir U, Stefansson K, van Duijn CM, Aulchenko YS, Cao A, Scuteri A, Schlessinger D, Uda M, Ruokonen A, Jarvelin MR, Waterworth DM, Vollenweider P, Peltonen L, Mooser V, Abecasis GR, Wareham NJ, Sladek R, Froguel P, Watanabe RM, Meigs JB, Groop L, Boehnke M, McCarthy MI, Florez JC, Barroso I. Novel genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* 2010;42:105–116
  20. Devlin B, Roeder K. Genomic control for association studies. *Biometrics* 1999;55:997–1004
  21. Ioannidis JP, Patsopoulos NA, Evangelou E. Heterogeneity in meta-analyses of genome-wide association investigations. *PLoS One* 2007;2:e841
  22. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, Raychaudhuri S, McCarrall SA, Langenberg C, Hofmann OM, Dupuis J, Qi L, Segrè AV, Hoek Mv, Navarro P, Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, Bonnycastle LL, Boström KB, Bravenboer B, Bumpstead S, Burt NP, Charpentier G, Chines PS, Cornelis M, Cooper DJ, Crawford G, Doney AS, Elliott KS, Elliott AL, Erdos MR, Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PR, Jørgensen T, Kao WH, Klopp N, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieveira A, Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu N, Nilsson P, Owen KR, Payne F, Perry JR, Petersen A, Platou C, Proença C, Prokopenko I, Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparso T, Strassburger K, Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van Haften TW, Herpt Tv, van Vliet-Ostapchouk JV, Walters GB, Weedon MN, Wijmenga C, Witteman J, investigators TM, consortium TG, Bergman RN, Cauchi S, Collins FS, Gloy AL, Gyllenstein U, Hansen T, Hide WA, Hitman GA, Hofman A,



- Hunter DJ, Hveem K, Laakso M, Mohlke KL, Morris AD, Palmer CN, Pramstaller PP, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden A, Walker M, Wareham NJ, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, Hattersley AT, Hu FB, Meigs JB, Pankow JS, Pedersen O, Wichmann H, Barroso I, Florez JC, Frayling TM, Groop L, Sladek R, Thorsteinsdottir U, Wilson JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, McCarthy MI: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet* 2010;42:579–589
23. Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. *Stat Med* 2008;27:157–172; discussion 207–112
  24. Saxena R, Hivert M, Langenberg C, Tanaka T, Pankow JS, Vollenweider P, Lyssenko V, Bouatia-Naji N, Dupuis J, Jackson AU, Kao WHL, Li M, Glazer NL, Manning AK, Luan J, Stringham HM, Prokopenko I, Johnson T, Grarup N, Lecoeur C, Shadrer P, O'Connell J, Ingelsson E, Couper DJ, Rice K, Song K, Andreasen CH, Dina C, Kottgen A, Bacquer OL, Pattou F, Taneera J, Steinthorsdottir V, Rybin D, Ardlie K, Sampson M, Qi L, Hoek MV, Weedon MN, Aulchenko YS, Voight BF, Grallert H, Balkau B, Bergman RN, Bielinski SJ, Bonnefond A, Bonnycastle LL, Borch-Johnsen K, Böttcher Y, Brunner E, Buchanan TA, Bumpstead SJ, Cavalcanti-Proena C, Charpentier G, Chen YI, Chines PS, Collins FS, Cornelis M, Crawford GJ, Delplanque J, Doney A, Egan JM, Erdos MR, Firmann M, Forouhi NG, Fox CS, Goodarzi MO, Graessler J, Hingorani A, Isomaa B, Jrgensen T, Kivimaki M, Kovacs P, Krohn K, Kumari M, Lauritzen T, Levy-Marchal C, Mayor V, McAteer JB, Meyre D, Mitchell BD, Mohlke KL, Morken MA, Narisu N, Palmer CNA, Pakyz R, Pascoe L, Payne F, Pearson D, Rathmann W, Sandbaek A, Sayer AA, Scott LJ, Sharp SJ, Sijbrands E, Singleton A, Siscovick DS, Smith NL, Sparso T, Swift A, Syddall H, Thorleifsson G, Trjes A, Tuomi T, Tuomilehto J, Valle TT, Waeber G, Walley A, Waterworth DM, Zeggini E, Zhao JH, consortium G, Illig T, Wichmann HE, Wilson JF, Duijn Cv, Hu FB, Morris AD, Frayling TM, Hattersley AT, Thorsteinsdottir U, Stefansson K, Nilsson P, Syvnen A, Shuldiner AR, Walker M, Bornstein SR, Schwarz P, Williams GH, Nathan DM, Kuusisto J, Laakso M, Cooper C, Hansen T, Pedersen O, Marmot M, Ferrucci L, Mooser V, Stumvoll M, Loos RJ, Altshuler D, Psaty BM, Rotter JJ, Boerwinkle E, Florez JC, McCarthy MI, Boehnke M, Barroso I, Sladek R, Froguel P, Meigs JB, Groop L, Wareham NJ, Watanabe RM: Genetic variation in GIPR impacts the glucose and insulin responses to an oral glucose challenge. *Nat Genet* 2010;42:142–148
  25. Ganesh SK, Zakai NA, van Rooij FJ, Soranzo N, Smith AV, Nalls MA, Chen MH, Kottgen A, Glazer NL, Dehghan A, Kuhnel B, Aspelund T, Yang Q, Tanaka T, Jaffe A, Bis JC, Verwoert GC, Teumer A, Fox CS, Guralnik JM, Ehret GB, Rice K, Felix JF, Rendon A, Eiriksdottir G, Levy D, Patel KV, Boerwinkle E, Rotter JJ, Hofman A, Sambrook JG, Hernandez DG, Zheng G, Bandinelli S, Singleton AB, Coresh J, Lumley T, Uitterlinden AG, Vangils JM, Launer LJ, Cupples LA, Oostra BA, Zwaginga JJ, Ouwehand WH, Thein SL, Meisinger C, Deloukas P, Nauck M, Spector TD, Gieger C, Gudnason V, van Duijn CM, Psaty BM, Ferrucci L, Chakravarti A, Greinacher A, O'Donnell CJ, Witterman JC, Furth S, Cushman M, Harris TB, Lin JP: Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. *Nat Genet* 2009;41:1191–1198
  26. Soranzo N, Spector TD, Mangino M, Kuhnel B, Rendon A, Teumer A, Willenborg C, Wright B, Chen L, Li M, Salo P, Voight BF, Burns P, Laskowski RA, Xue Y, Menzel S, Altshuler D, Bradley JR, Bumpstead S, Burnett MS, Devaney J, Doring A, Elosua R, Epstein SE, Erber W, Falchi M, Garner SF, Ghorri MJ, Goodall AH, Gwilliam R, Hakonarson HH, Hall AS, Hammond N, Hengstenberg C, Illig T, König IR, Knouff CW, McPherson R, Melander O, Mooser V, Nauck M, Nieminen MS, O'Donnell CJ, Peltonen L, Potter SC, Prokisch H, Rader DJ, Rice CM, Roberts R, Salomaa V, Sambrook J, Schreiber S, Schunkert H, Schwartz SM, Serbanovic-Canic J, Sinisalo J, Siscovick DS, Stark K, Surakka I, Stephens J, Thompson JR, Volker U, Volzke H, Watkins NA, Wells GA, Wichmann HE, Van Heel DA, Tyler-Smith C, Thein SL, Kathiresan S, Perola M, Reilly MP, Stewart AF, Erdmann J, Samani NJ, Meisinger C, Greinacher A, Deloukas P, Ouwehand WH, Gieger C: A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. *Nat Genet* 2009;41:1182–1190
  27. Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chevre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, Riveline JP, Hadjadj S, Gallois Y, Czernichow S, Hercberg S, Kaakinen M, Wiesner S, Charpentier G, Levy-Marchal C, Elliott P, Jarvelin MR, Horber F, Dina C, Pedersen O, Sladek R, Meyre D, Froguel P: Genetic variant in HK1 is associated with a proanemic state and HbA<sub>1c</sub> but not other glycemic control-related traits. *Diabetes* 2009;58:2687–2697
  28. Rijkssen G, Akkerman JW, van den Wall Bake AW, Hofstede DP, Staal GE: Generalized hexokinase deficiency in the blood cells of a patient with nonspherocytic hemolytic anemia. *Blood* 1983;61:12–18
  29. Bianchi M, Magnani M: Hexokinase mutations that produce nonspherocytic hemolytic anemia. *Blood Cells Mol Dis* 1995;21:2–8
  30. Schmidt PJ, Toran PT, Giannetti AM, Bjorkman PJ, Andrews NC: The transferrin receptor modulates Hfe-dependent regulation of hepcidin expression. *Cell Metab* 2008;7:205–214
  31. Conte D, Manachino D, Colli A, Guala A, Aimo G, Andreoletti M, Corsetti M, Fraquelli M: Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. *Ann Intern Med* 1998;128:370–373
  32. Phelps G, Chapman I, Hall P, Braund W, Mackinnon M: Prevalence of genetic haemochromatosis among diabetic patients. *Lancet* 1989;2:233–234
  33. Little RR, Rohlfing CL, Wiedmeyer HM, Myers GL, Sacks DB, Goldstein DE: The national glycohemoglobin standardization program: a five-year progress report. *Clin Chem* 2001;47:1985–1992